Relationship of ethnicity and overall survival (OS) in Asian patients (pts) on sorafenib for advanced hepatocellular carcinoma (HCC) in British Columbia, Canada

被引：0
|
作者：
Peixoto, Renata D'Alpino [1 ]
Renouf, Daniel John [1 ]
Gill, Sharlene [1 ]
Cheung, Winson Y. [1 ]
Kennecke, Hagen F. [1 ]
Lim, Howard John [1 ]
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.311
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
311
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S).
    Meyers, Daniel E.
    Lee-Ying, Richard M.
    Alghamdi, Mohammed Abdullah
    Cheung, Winson Y.
    Samawi, Haider
    Tam, Vincent C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [2] Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma
    Peixoto, Renata D'Alpino
    Renouf, Daniel J.
    Gill, Sharlene
    Cheung, Winson Y.
    Lim, Howard J.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2014, 5 (04) : 259 - 264
  • [3] Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S): Results from a Canadian multi-centre HCC database
    Meyers, D. E.
    Lee-Ying, R.
    Alghamdi, M.
    Sim, H-W.
    Zaborska, V. O.
    Ko, Y-J.
    Raycraft, T.
    Batuyong, E.
    Cheung, W. Y.
    Samawi, H.
    Davies, J. M.
    Tam, V. C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)
    Ryoo, B-Y.
    Ren, Z.
    Kim, T-Y.
    Pan, H.
    Rau, K-M.
    Choi, H. J.
    Park, J-W.
    Kim, J. H.
    Yen, C-J.
    Kim, B-H.
    Zhou, D.
    Straub, J.
    Zhao, C.
    Qin, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Objective response (OR) by mRECIST to predict overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with sorafenib in the SILIUS trial
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Ogawa, Chikara
    Chiba, Yasutaka
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [6] Association of hypertension with overall outcome in patients taking sorafenib in advanced hepatocellular carcinoma (HCC)
    Kim, R. D.
    Byrne, M. T.
    Hammel, J.
    El-Gazzaz, G.
    Aucejo, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Overall survival (OS) in patients (pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): A real-world retrospective study.
    Hennenfent, Kristin L.
    Girvan, Allicia C.
    Chaudhry, Aafia
    Abada, Paolo
    Sheffield, Kristin
    Herren, Catherine K.
    Raju, Aditya
    Farrelly, Eileen
    Bowman, Lee
    Landsman-Blurnberg, Pamela
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] DERMATOLOGIC ADVERSE EVENTS WITHIN THE FIRST 60 DAYS OF SORAFENIB TREATMENT ARE ASSOCIATED WITH BETTER OVERALL SURVIVAL (OS) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)
    Reig, M.
    Rodriguez de Lope, C.
    Llarch, N.
    Forner, A.
    Torres, F.
    Rios, J.
    Boix, L.
    Rimola, J.
    Darnell, A.
    Ayuso, C.
    Bruix, J.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S113 - S113
  • [9] Overall survival predictors in hepatocellular carcinoma patients treated with sorafenib
    da Costa Ferreira, Caroline Petersen
    Ribeiro, Mauricio Alves
    Szutan, Luiz Arnaldo
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2020, 66 (03): : 275 - 283
  • [10] Phase Ib/II study of sorafenib (SOR) and pembrolizumab (PEM) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Iyer, Renuka
    Sonti, Sahithi
    Mahalingam, Devalingam
    Mukherjee, Sarbajit
    Chakraborty, Sayan
    Attwood, Kristopher
    George, Anthony
    Maguire, Orla
    Minderman, Hans
    Fountzilas, Christos
    CANCER RESEARCH, 2024, 84 (07)
12345